Clinical characteristics and clinicopathological correlations of bilateral breast cancer in China:A multicenter study from Chinese Society of Breast Surgery(CSBrS-006)

Objective:To investigate the clinical characteristics and clinicopathological correlations of bilateral breast cancer(BBC)in China.Methods:Data of 440 patients diagnosed with BBC in 2018 were collected from 33 centers of the Chinese Society of Breast Surgery.Demographic characteristics,bilateral tumor characteristics,and comprehensive treatment data were obtained.Correlations between the clinicopathological characteristics of bilateral tumors were analyzed.Results:The proportion of BBC was 0.22%-3.08%.A total of 33(7.5%)patients had a family history of malignant tumors,304(69.1%)patients had synchronous BBC.Only 1(0.2%)patient was male.More than half of all patients received concurrent or asynchronous endocrine/chemotherapy,32.5%of all human epidermal growth factor receptor 2(HER2)-positive patients received HER2-targeted therapy,and approximately 21.6%of all patients received radiotherapy.The most common pathological cancer type was invasive ductal cancer(>60%).Approximately 70%of all patients had bilateral hormone receptor(HR)-positive tumors and presented with a single breast mass.Significant correlations were found with pathological type,histological grade,locations of tumor,molecular subtype,Ki-67 index,tumor site and size of bilateral tumors.Results of the subgroup analysis showed more clinicopathological characteristics when synchronous BBC was compared with metachronous BBC.Conclusions:In China,the clinicopathological characteristics of bilateral tumors showed significant correlations,and more significant clinicopathological correlations were observed when synchronous BBC was compared with metachronous BBC.

Skeletal muscle as a molecular and cellular biomarker of disease progression in amyotrophic lateral sclerosis:a narrative review

Amyotrophic lateral sclerosis is a fatal multisystemic neurodegenerative disease with motor neurons being a primary target.Although progressive weakness is a hallmark feature of amyotrophic lateral sclerosis,there is considerable heterogeneity,including clinical presentation,progression,and the underlying triggers for disease initiation.Based on longitudinal studies with families harboring amyotrophic lateral sclerosis-associated gene mutations,it has become apparent that overt disease is preceded by a prodromal phase,possibly in years,where compensatory mechanisms delay symptom onset.Since 85-90%of amyotrophic lateral sclerosis is sporadic,there is a strong need for identifying biomarkers that can detect this prodromal phase as motor neurons have limited capacity for regeneration.Current Food and Drug Administration-approved therapies work by slowing the degenerative process and are most effective early in the disease.Skeletal muscle,including the neuromuscular junction,manifests abnormalities at the earliest stages of the disease,before motor neuron loss,making it a promising source for identifying biomarkers of the prodromal phase.The accessibility of muscle through biopsy provides a lens into the distal motor system at earlier stages and in real time.The advent of“omics”technology has led to the identification of numerous dysregulated molecules in amyotrophic lateral sclerosis muscle,ranging from coding and non-coding RNAs to proteins and metabolites.This technology has opened the door for identifying biomarkers of disease activity and providing insight into disease mechanisms.A major challenge is correlating the myriad of dysregulated molecules with clinical or histological progression and understanding their relevance to presymptomatic phases of disease.There are two major goals of this review.The first is to summarize some of the biomarkers identified in human amyotrophic lateral sclerosis muscle that have a clinicopathological correlation with disease activity,evidence of a similar dysregulation in the SOD1G93A mouse during presymptomatic stages,and evidence of progressive change during disease progression.The second goal is to review the molecular pathways these biomarkers reflect and their potential role in mitigating or promoting disease progression,and as such,their potential as therapeutic targets in amyotrophic lateral sclerosis.

Clinicopathological aspects correlated with 1p/19q co-deletion in gliomas

Objective This study aims to select clinical and pathological aspects correlated with 1p /19q co-deletion in gliomas. Methods Samples of 56 glioma patients were collected. The status of chromosome 1p and 19q was detected by Fluorescence in Situ Hybridization (FISH) and the expression levels of nine

Focal-type,but not Diffuse-type,Amyloid Beta Plaques are Correlated with Alzheimer’s Neuropathology,Cognitive Dysfunction,and Neuroinflammation in the Human Hippocampus

Amyloid beta(Aβ)plaques are one of the hallmarks of Alzheimer’s disease(AD).However,currently available anti-amyloid therapies fail to show effectiveness in the treatment of AD in humans.It has been found that there are different types of Aβplaque(diffuse and focal types)in the postmortem human brain.In this study,we aimed to investigate the correlations among different types of Aβplaque and AD-related neuropathological and cognitive changes based on a postmortem human brain bank in China.The results indicated that focal plaques,but not diffuse plaques,significantly increased with age in the human hippocampus.We also found that the number of focal plaques was positively correlated with the severity of AD-related neuropathological changes(measured by the“ABC”scoring system)and cognitive decline(measured by the Everyday Cognitive Insider Questionnaire).Furthermore,most of the focal plaques were co-localized with neuritic plaques(identified by Bielschowsky silver staining)and accompanied by microglial and other inflammatory cells.Our findings suggest the potential of using focal-type but not general Aβplaques as biomarkers for the neuropathological evaluation of AD.